Singular Genomics Systems Stock Buy Hold or Sell Recommendation
| OMIC Stock | USD 21.42 0.48 2.19% |
Given the investment horizon of 90 days and your slightly conservative level of risk, our recommendation regarding Singular Genomics Systems is 'Hold'. Macroaxis provides Singular Genomics buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding OMIC positions.
Check out Singular Genomics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. In addition, we conduct extensive research on individual companies such as Singular and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Singular Genomics Systems. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
Singular |
Execute Singular Genomics Buy or Sell Advice
The Singular recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Singular Genomics Systems. Macroaxis does not own or have any residual interests in Singular Genomics Systems or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Singular Genomics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Hold
Market Performance | Good | Details | |
Volatility | Very risky | Details | |
Hype Condition | Low key | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Quite High | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Singular Genomics Trading Alerts and Improvement Suggestions
| Singular Genomics is way too risky over 90 days horizon | |
| Singular Genomics appears to be risky and price may revert if volatility continues | |
| Singular Genomics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 2.91 M. Net Loss for the year was (94.82 M) with loss before overhead, payroll, taxes, and interest of (24 K). | |
| Singular Genomics Systems currently holds about 287.98 M in cash with (73.65 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.05. | |
| Singular Genomics has a poor financial position based on the latest SEC disclosures | |
| Roughly 60.0% of the company shares are owned by institutional investors | |
| Latest headline from gurufocus.com: Disposition of 1212 shares by Andrew Spaventa of Singular Genomics subject to Rule 16b-3 |
Singular Genomics Returns Distribution Density
The distribution of Singular Genomics' historical returns is an attempt to chart the uncertainty of Singular Genomics' future price movements. The chart of the probability distribution of Singular Genomics daily returns describes the distribution of returns around its average expected value. We use Singular Genomics Systems price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Singular Genomics returns is essential to provide solid investment advice for Singular Genomics.
| Mean Return | 2.93 | Value At Risk | -6.36 | Potential Upside | 12.24 | Standard Deviation | 17.38 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Singular Genomics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Singular Stock Institutional Investors
| Shares | Tikvah Management Llc | 2024-06-30 | 10.6 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 726 | Tower Research Capital Llc | 2024-06-30 | 528 | Barclays Plc | 2024-06-30 | 409 | Bank Of America Corp | 2024-06-30 | 367 | Royal Bank Of Canada | 2024-06-30 | 87.0 | Rhumbline Advisers | 2024-06-30 | 55.0 | Bnp Paribas Arbitrage, Sa | 2024-06-30 | 36.0 | Capital Advisors, Ltd. Llc | 2024-06-30 | 33.0 | Deerfield Management Co | 2024-06-30 | 166.2 K | Arch Venture Corp | 2024-09-30 | 126.6 K |
Singular Genomics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Singular Genomics or Health Care Equipment & Supplies sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Singular Genomics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Singular stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 2.84 | |
β | Beta against Dow Jones | 0.81 | |
σ | Overall volatility | 17.66 | |
Ir | Information ratio | 0.16 |
Singular Genomics Volatility Alert
Singular Genomics Systems is displaying above-average volatility over the selected time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Singular Genomics' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Singular Genomics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Singular Genomics Fundamentals Vs Peers
Comparing Singular Genomics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Singular Genomics' direct or indirect competition across all of the common fundamentals between Singular Genomics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Singular Genomics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Singular Genomics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Singular Genomics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Singular Genomics to competition |
| Fundamentals | Singular Genomics | Peer Average |
| Return On Equity | -0.52 | -0.31 |
| Return On Asset | -0.24 | -0.14 |
| Operating Margin | (30.94) % | (5.51) % |
| Current Valuation | (8.33 M) | 16.62 B |
| Shares Outstanding | 2.51 M | 571.82 M |
| Shares Owned By Insiders | 13.90 % | 10.09 % |
| Shares Owned By Institutions | 60.22 % | 39.21 % |
| Number Of Shares Shorted | 71.17 K | 4.71 M |
| Price To Earning | 35.71 X | 28.72 X |
| Price To Book | 0.45 X | 9.51 X |
| Price To Sales | 20.20 X | 11.42 X |
| Revenue | 2.91 M | 9.43 B |
| Gross Profit | (24 K) | 27.38 B |
| EBITDA | (86.5 M) | 3.9 B |
| Net Income | (94.82 M) | 570.98 M |
| Cash And Equivalents | 287.98 M | 2.7 B |
| Cash Per Share | 4.05 X | 5.01 X |
| Total Debt | 75.29 M | 5.32 B |
| Debt To Equity | 0.20 % | 48.70 % |
| Current Ratio | 22.98 X | 2.16 X |
| Book Value Per Share | 72.74 X | 1.93 K |
| Cash Flow From Operations | (73.65 M) | 971.22 M |
| Short Ratio | 2.30 X | 4.00 X |
| Earnings Per Share | (34.68) X | 3.12 X |
| Price To Earnings To Growth | (0.15) X | 4.89 X |
| Target Price | 12.45 | |
| Number Of Employees | 255 | 18.84 K |
| Beta | 1.51 | -0.15 |
| Market Capitalization | 55.01 M | 19.03 B |
| Total Asset | 265.47 M | 29.47 B |
| Retained Earnings | (337.6 M) | 9.33 B |
| Working Capital | 173.94 M | 1.48 B |
| Net Asset | 265.47 M |
Note: Acquisition by Jyotsna Ghai of 250 shares of Singular Genomics subject to Rule 16b-3 [view details]
Singular Genomics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Singular . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Singular Genomics Buy or Sell Advice
When is the right time to buy or sell Singular Genomics Systems? Buying financial instruments such as Singular Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Singular Genomics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Wholesale Thematic Idea Now
Wholesale
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Wholesale theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Wholesale Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Singular Genomics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Singular Genomics. If investors know Singular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Singular Genomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (34.68) | Revenue Per Share 1.107 | Quarterly Revenue Growth 0.459 | Return On Assets (0.24) | Return On Equity (0.52) |
The market value of Singular Genomics Systems is measured differently than its book value, which is the value of Singular that is recorded on the company's balance sheet. Investors also form their own opinion of Singular Genomics' value that differs from its market value or its book value, called intrinsic value, which is Singular Genomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Singular Genomics' market value can be influenced by many factors that don't directly affect Singular Genomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Singular Genomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Singular Genomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Singular Genomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.